CANNABIS AND MS: HELPING PATIENTS UNDERSTAND RISKS AND BENEFITS
SESSION 3: PHARMACOLOGY AND INTERACTIONS, TRIAL DATA, DMTs, AND CASE STUDIES
OCTOBER 28, 2020
7:00 – 8:00 pm ET
MS health professionals may be involved in the decision-making process about cannabis and provide care to those with MS who use cannabis. However, numerous surveys indicate that health professionals lack knowledge and competence in this area and thus may be unable to provide objective cannabis information, facilitate informed cannabis decision-making for their patients, or optimize safety and effectiveness in those patients who choose to use cannabis. The goal of this three-part webinar series is to address this situation by providing participants with evidence-based information about the effects of cannabis on MS symptoms, including pain and spasticity. Featured speaker Allen C. Bowling, MD, PhD, will describe the current understanding of pharmacology, efficacy, and adverse events, including drug interactions, as well as the role of the FDA in licensing and monitoring products and the lack of oversight for products purchased in cannabis dispensary locations.
COMMERCIAL SUPPORT STATEMENT
This activity is supported by an independent educational grant from Greenwich Biosciences.
At the conclusion of this session, learners will be able to:
- Discuss cannabis pharmacology, including the endocannabinoid system.
- Critically analyze MS clinical trial data.
- Describe detailed interactions of cannabis with conventional medications, including MS disease-modifying therapies.
This activity has been designed to meet the educational needs of physicians, advanced practice clinicians, nursing professionals, pharmacists, psychologists, social workers, and other members of the healthcare team involved in the management of patients with MS.
ACCREDITATION AND CREDIT DESIGNATION
In support of improving patient care, the Consortium of Multiple Sclerosis Centers (CMSC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The CMSC designates this live activity for 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The CMSC designates this live activity for 1.0 contact hour of continuing nursing education.
This knowledge-based activity (JA4008165-0000-20-056-L01-P) qualifies for 1.0 contact hour (0.1 CEUs) of continuing pharmacy education credit.
The Consortium of Multiple Sclerosis Centers has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
This activity is awarded 1.0 CE credits.
As a Jointly Accredited Organization, the Consortium of Multiple Sclerosis Centers (CMSC) is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. CMSC maintains responsibility for this course. Social workers completing this course receive 1.0 continuing education credit.
CERTIFICATE OF ATTENDANCE FOR OTHER HEALTHCARE PROFESSIONALS
A Certificate of Attendance will be given upon completion of course requirements enabling attendees to register their credit with the appropriate licensing boards or associations. Attendees may apply for other accreditations using procedures established by specific organizations.
DISCLOSURE OF CONFLICTS OF INTEREST
It is the policy of CMSC to ensure balance, independence, objectivity, and scientific rigor in all educational activities. All faculty, planning committee members, content reviewers, and staff participating in this activity have disclosed any relevant financial relationships they or their significant other have had within the previous 12 months with manufacturers of any commercial products/devices and/or providers of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. All presentations were reviewed by an independent clinician with no relevant financial relationships for the purpose of resolution of any identified conflict of interest and a determination of evidence-base and fair balance.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
Allen Bowling, MD, PhD has disclosed the following relevant financial relationships: Royalty: Springer Publishing; Consulting Fee: Celgene/Bristol Myers Squibb, EMD Serono, Inc., Novartis Pharmaceuticals Corporation, Greenwich Biosciences; Speakers Bureau: Celgene/Bristol Myers Squibb, EMD Serono, Inc., Genentech, Novartis Pharmaceuticals Corporation, Sanofi Genzyme, Greenwich Biosciences.
June Halper, MSN, APN-C, MSCN, FAAN (Planner and Reviewer) has disclosed no relevant financial relationships.
Laurie Scudder, DNP, NP (Reviewer) has disclosed no relevant financial relationships.
The staff at CMSC have disclosed no relevant financial relationships.
There is no fee to participate in this activity.
HOW TO RECEIVE CREDIT FOR THE LIVE WEBINAR
To successfully complete this live activity, participants must review the accreditation information, including learning objectives and faculty disclosures, view the webinar, and complete the evaluation. Participants will receive a detailed email to complete the evaluation and claim their credit the day after the live webinar.
CMSC presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. CMSC assumes no liability for the information herein.
For information about the accreditation of this program, please contact the CMSC at [email protected] or 201-487-1050, ext. 102.